ST. LOUIS, April 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration 510(k) clearance for the Synchrony™ system.
Read more at globenewswire.comStereotaxis Announces FDA Clearance and Launch of Synchrony System
Provided By GlobeNewswire – Last update: